SEARCH:   Advanced

Blood, 1 April 2005, Vol. 105, No. 7, pp. 2991-2994. Prepublished online as a Blood First Edition Paper on December 16, 2004; DOI 10.1182/blood-2004-09-3715. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-09-3715v1 105/7/2991    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Flierman, R. Articles by van Laar, J. M. Search for Related Content PubMed PubMed Citation Articles by Flierman, R. Articles by van Laar, J. M. Related Collections Immunobiology Transplantation Brief Reports Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Brief report Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantation Roelof Flierman, Hendrik J. Witteveen, Ellen I. H. van der Voort, Tom W. J. Huizinga, René R. P. de Vries, Willem E. Fibbe, René E. M. Toes, and Jacob M. van Laar From the Departments of Rheumatology, Immunohematology and Blood Transfusion, and Hematology, Leiden University Medical Center, Leiden, The Netherlands. Systemic autoimmune disease (AID) can be controlled with conventional therapies in most patients. However, relapses are common, leading to progressive disability and premature death. Nonmyeloablative conditioning and allogeneic bone marrow transplantation (BMT) could be an effective treatment for severe AID, because of mild toxicity of the conditioning and the potential benefits of donor chimerism. We examined the effects of this treatment in experimental autoimmune arthritis. Our results demonstrate the induction of complete donor chimerism and significant suppression of disease activity. No clinical graft-versus-host disease (GVHD) was observed. The beneficial effects were most likely caused by the elimination of plasma cells producing pathogenic autoantibodies, because these antibodies disappeared rapidly after BMT. Although this type of treatment was effective in organ-specific T-cell-mediated AID, the present study provides convincing evidence that nonmyeloablative conditioning and allogeneic BMT can effectively treat severe B-cell-mediated AID with a systemic inflammatory component. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: From animals to clinic: nonmyeloablative conditioning and allogeneic bone marrow transplantation in autoimmune disease Richard K. Burt Blood 2005 105: 2623-2624. [Full Text] [PDF] This article has been cited by other articles: R. Flierman, G. Westerhuis, M. Hameetman, L. M. van Duivenvoorde, T. van Hall, J. M. van Laar, W. E. Fibbe, and R. E. M. Toes Targeting host B-cell immune responses by persistent donor NK-cell alloreactivity following nonmyeloablative allogeneic stem cell transplantation Blood, June 15, 2007; 109(12): 5524 - 5525. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020